Benson M D, Dasgupta N R, Rao R. Diagnosis and screening of patients withhereditary transthyretin amyloidosis(hattr): current strategies and guidelines[J]. Clin Risk Manag, 2020, 14(16):749-758.
[2]
Teng C, Li P Y, Bae J Y, et al. Diagnosis and treatment oftransthyretin-related amyloidosis cardiomyopathy[J]. Clin Cardiol, 2020,43(11):1223-1231.
[3]
Auer G M, Rettl R,Ablasser K,et al. ATTR Amyloidosis in austria:prevalence and epidemiological hot spots[J].Clin Med, 2020, Jul 14;9(7):2234.
[4]
Adams D,Gonzalez D A,O’Riordan W D,et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis[J]. New Engl J Med,2018,379(1):11-21.
Rizio A A, Broderick L E, White M K,et al. Content Validation of the ATTR amyloidosis patient symptom survey: findings from patient and clinician cognitive debriefing interviews[J]. Patient Relat Outcome Meas, 2020, 26(11):149-160.
[7]
Klaassen S H, Veldhuisen D J, Nienhuis H L,et al. Cardiac transthyretin derived amyloidosis: an emerging target inheart failure with preserved ejection fraction[J]. Card Fail Rev, 2020, 7(6):21.
[8]
Gertz M,Adams D,Ando Y, et al. Avoiding misdiagnosis: expert consensusrecommendations for the suspicion and diagnosis of transthyretin amyloidosis forthe general practitioner[J]. BMC Fam Pract, 2020, 23(1):198.
[9]
Beckius S,Shah K.Intracranial and systemic manifestations of familial leptomeningeal amyloidosis, as seen on CT and MRI[J]. Radiol Case Rep, 2018, 13(6): 1179-1184.
[10]
Adams D, Ando Y, Beirão J M, et al. Expert consensus recommendations to improvediagnosis of ATTR amyloidosis with polyneuropathy[J].J Neurol,2021, 268(6):2109-2122.
2023, Vol. 34 
